Pediatric fever of uncertain source: Difference between revisions

No edit summary
Line 17: Line 17:
*RSV+ infants aged 29-60 days, the SBI rate was 5.5%, all of which were UTIs
*RSV+ infants aged 29-60 days, the SBI rate was 5.5%, all of which were UTIs


==Tintinalli Textbook Protocol==
==Diagnosis & Management==
 
- '''Management of patients who are well-appearing, ''vaccinated'', and no clinical source of fever'''
 
{| class="wikitable"
|-
| Age Group
| Evaluation
| Treatment
|-
|
57d-6mo, ≥38
 
Non-UTI SBI incidence is estimated to be negligible
 
<span class="Apple-style-span" style="line-height: 17px">UTI is 3%–8%</span>&nbsp;
 
<br>
 
|
UA and Ucx alone
 
OR
 
treat 57-90d using Philadelphia Protocol
 
|
Discharge if negative
 
Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient
 
Admit and tx with [[ceftriaxone]] if fail criteria for d/c
 
|-
|
57d-6mo, ≥39 (102.2)
 
SBI incidence is estimated &lt;1%;
 
non-UTI SBI incidence is estimated to be negligible.
 
UTI is 3%–8%
 
|
UA and Ucx alone
 
OR
 
UA and Ucx + CBC + blood cx
 
|
:
 
Discharge if negative
 
Treat for UTI as above
 
If WBC&gt;15K&nbsp;consider treatment with [[ceftriaxone]] 50 mg/kg IV/IM, and follow-up in 24hr
 
If WBC&gt;20K&nbsp;consider CXR and CSF
 
|-
|
&nbsp;6–36 mo
 
Non-UTI SBI incidence is &lt;0.4%&nbsp;
 
UTI in girls ≤8%
 
UTI in boys (&lt;12 mo) ≤ 2%
 
Uncircumcised boys (1–2 y) remains 2%
 
|
UA and Ucx in:
 
(girls 6-24mo)
 
(circ 6-12mo)
 
(uncirc 6-24mo)
 
|
Discharge if negative
 
Treat for UTI as above as outpatient
 
|-
| &gt;36mo
| No further w/u is routinely necessary
| <br>
|}
 
== Harbor-UCLA Protocol  ==
=== 0-28dy  ===
=== 0-28dy  ===
{| class="wikitable"
{| class="wikitable"
Line 192: Line 99:
| '''Disposition & Follow-Up'''  
| '''Disposition & Follow-Up'''  
|-
|-
| '''T>=38 + Toxic'''
| '''T≥38° + Toxic'''
|  
|  
*CBC  
*CBC  
Line 204: Line 111:
| Admit  
| Admit  
|-
|-
| '''T>=39°C + Well + Non-complete [[Prevnar]]'''
| '''T≥39°C + Well + Non-complete [[Prevnar]]'''
(No [[Prevnar]] or <4 wks post 1st [[Prevnar]] dose)
(No [[Prevnar]] or <4 wks post 1st [[Prevnar]] dose)
|  
|  
Line 214: Line 121:
| Outpatient (24 hour follow-up)
| Outpatient (24 hour follow-up)
|-
|-
| '''T>=39°C + Well + [[Prevnar]]'''
| '''T≥39°C + Well + [[Prevnar]]'''
(2 [[Prevnar]] or ≥4 wks post 1st [[Prevnar]] dose)
(2 [[Prevnar]] or ≥4 wks post 1st [[Prevnar]] dose)
|  
|  
Line 225: Line 132:
| Outpatient (48hour f/u)
| Outpatient (48hour f/u)
|-
|-
| '''T>=38-38.9°C + Well'''
| '''T≥38-38.9°C + Well'''
| Consider UA, CXR based on symptoms, etc
| Consider UA, CXR based on symptoms, etc
| Treat [[cystitis]] or [[PNA]] if positive
| Treat [[cystitis]] or [[PNA]] if positive

Revision as of 21:45, 28 April 2015

Background

  • Medicine is an art as well as science, practice clinical judgment when using guidelines
  • Preemies: Count age by estimated postconception date (not by actual delivery date) for 1st-90d
  • If RSV+ or influenza+
    • Low risk of bacterial illness
    • Still some risk of concurrent UTI

Facts and Figures from ACEP's Clinical Policy on Pediatric Fevers

  • 7% of patients < 2 years old with fever have PNA, however the etiology (viral/bacterial) or even the presence of pneumonia has low inter-observer reliability even among pediatric radiologists
  • 4% Prevalence of UTI with common other sources of fever (OM, viral URI, et cetera)
  • 1.5-2% background prevalence of asymptomatic bacteruria in healthy afebrile controls
  • 0.3% Rate of occult bactremia with healthy, well-appearing child who has a fever 2-24 months
  • 0.3% of previously well children aged 3-36 months who have a fever without a source will develop significant sequelae, 0.03% will develop sepsis or meningitis

Concomitant RSV infection

  • In RSV+ (by PCR) neonates aged 0-28 days, 6.1% had UTIs and 3.7% were bactremic; there was no difference in rates of SBI between RSV+ and RSV- neonates in a large prospective multicenter study entailing 1,248 children
  • RSV+ infants aged 29-60 days, the SBI rate was 5.5%, all of which were UTIs

Diagnosis & Management

0-28dy

Child Appearance Work Up Treatment Disposition & Follow-up Comments
Temp ≥38°

Toxic or Well

  • CBC
  • Blood Cx
  • UA, Ucx
  • LP-CSF
  • CXR
  • +/- Stool studies (if diarrhea)
Admit SBI incidence
  • Ill appearing: 13%–21%
  • Not ill appearing: <5%

^Acyclovir if:

  • HSV infection in baby or mother
  • CSF pleocytoisis
  • Concerning skin lesions
  • Seizures
  • Abnormal LFTs

28dy-90dy

Appearance Work Up Treatment Disposition & Follow-Up
Temp≥38° + Toxic
  • CBC
  • Blood Cx
  • UA, Ucx
  • LP-CSF
  • +/- CXR
  • +/- Stool studies (if diarrhea)
Admit

Temp≥°38 + Well

  • CBC
  • Blood Cx
  • UA, UCx
  • +/- LP-CSF (must do before giving antibiotics)
  • +/- CXR
Workup(+): Antibiotics and admit

Workup(-): ?antibiotics; home with 24 follow-up

^^Can use ceftriaxone 50-100 mg/kg, but concern for bilirubin displacement

  • Consider CXR for:
    • Respiratory symptoms
    • Fever >48 hrs
    • Tachypnea
    • Hypoxia

^Acyclovir if:

  • HSV infection in baby or mother
  • CSF pleocytoisis
  • Concerning skin lesions
  • Seizures
  • Abnormal LFTs

90dy-36mo

Appearance Work Up Treatment Disposition & Follow-Up
T≥38° + Toxic
  • CBC
  • Blood Cx
  • UA, UCx
  • LP-CSF
  • CXR^
Admit
T≥39°C + Well + Non-complete Prevnar

(No Prevnar or <4 wks post 1st Prevnar dose)

  • UA, Urine culture
  • CBC
  • +/- CXR
If WBC(+): Outpatient (24 hour follow-up)
T≥39°C + Well + Prevnar

(2 Prevnar or ≥4 wks post 1st Prevnar dose)

  • Urine workup (UA, UCx) for:
    • Circumcised males <6 months
    • Uncircumcised males <12 months
    • All females
  • +/- CXR
Treat cystitis or PNA if postitive Outpatient (48hour f/u)
T≥38-38.9°C + Well Consider UA, CXR based on symptoms, etc Treat cystitis or PNA if positive Outpatient (48-72 hour follow-up)
  • Consider CXR for:
    • Respiratory symptoms
    • Fever >48 hrs
    • Tachypnea
    • Hypoxia

Work-Up Results

  • WBC: 5-15, ANC <10k, <1,500 bands
  • UA: (-)Gm Stain, (-) leuks, (-) nitrite, <5-10 wbc/hpf
  • CSF: <8wbc, (-) Gm Stain
  • When diarrhea present, <5 wbc

If low-risk criteria below not met, LP (if not done) and admit for inpt abx

Managment

  • Treat source


Acetaminophen Pediatric Dosing Chart

Weight (kg) Weight (lbs) Age Dosage (mg)
3-4 6-11 0-3 mo 40
5-7 12-17 4-11 mo 80
8-10 18-23 1-2 y 120
11-15 24-35 2-3 y 160
16-21 36-47 4-5 y 240
22-26 48-59 6-8 y 320
27-32 60-71 9-10 y 400
33-43 72-95 11 y 480
Dosage can be given q6 hours

See Also

External Links

Source s

  • Clinical Policy for Children Younger Than Three Years Presenting to the Emergency Department With Fever. Annuals of Emergency Medicine 2003 42. 530-545
  • Risk of Serious Bacterial Infection in Young Febrile Infants With Respiratory Syncytial Virus Infections. Levine et all. PEDIATRICS Vol. 113 No. 6 June 1, 2004 pp. 1728 -1734